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Abstract The aim of this study was to investigate the
distribution of a calcium-inhibitable adenylyl cyclase type VI
(type VI AC) in the central nervous system using an antiserum
directed against the N-terminus of type VI AC. Our results
indicate that type VI AC immunoreactivity is generally
expressed in many brain regions with different levels of intensity.
Most interestingly, the majority of the detected type VI AC
immunoreactivity is present in cells of neuronal phenotype.
Double immunostaining of type VI AC and markers of various
neurotransmitter systems suggest that type VI AC might
participate in regulation of the classical neurotransmitter
systems and therefore appeared to play a very important role
in the central nervous system.
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1. Introduction
Genes of at least 9 distinct mammalian adenylyl cyclases
(AC), which can be further divided into ¢ve subfamilies,
have been reported [1]. These enzymes can all be activated
by the K subunit of Gs protein to synthesize cAMP. Never-
theless, GsK protein stimulates each AC in a fundamentally
distinct manner [2]. Likewise, individual AC isozyme exhibits
di¡erent susceptibility to GiK-mediated inhibition [3]. Intra-
cellular Ca2 concentrations ([Ca2]i) also play a critical reg-
ulatory role in modulating AC activity. Some AC isozymes
(type I AC and type VIII AC) can be activated by Ca2 in the
presence of calmodulin [4], while type V AC and type VI AC
are directly inhibited by sub-micromolar concentrations of
calcium. In addition, protein kinase C (PKC) has been impli-
cated in modulating activities of some ACs positively (types II
and V adenylyl cyclases), but that of type VI negatively [5^7].
This heterogenous multigene AC family thus appears to play
a very critical role in integrating multiple signals. For exam-
ple, Marjamaki and colleagues [8] recently suggested that reg-
ulation of the cellular cAMP levels by G protein-coupled re-
ceptors might depend on the isoforms of AC expressed in the
cells and the phosphorylation states of these ACs.
At present, all of the cloned mammalian ACs were found to
be present in brain [8], suggesting a unique and critical role
for ACs in mediating the functions of the central nervous
system (CNS). For example, cyclic AMP-dependent mecha-
nisms have been implicated in release of neurotransmitter [9]
and long-term memory [10]. The most abundant ACs in CNS
are types I, II, and V ACs [4]. In contrast, no signi¢cant level
of type VI AC transcript was observed by the in situ hybrid-
ization technique in any discrete brain region, although the
expression of type VI AC mRNA could be detected in the
brain using Northern blot analysis or the RT-PCR technique
[4]. Since type VI AC can be inhibited by Ca2, by protein
kinase A (PKA), or by PKC [4,7,11], type VI AC might in-
tegrate multiple diverse signals which occur constantly in the
nervous system. To understand the neuronal signi¢cance of
this Ca2-inhibitable AC, we have examined the protein ex-
pression patterns of type VI AC in rat brain by immunocy-
tochemical staining using a subtype-speci¢c antiserum. Our
data suggest that type VI AC exists predominantly in neurons,
and might play a critical role in multiple signal integration.
2. Materials and methods
2.1. Preparation of antibody
Oligopeptides corresponding to amino acids 1^19 of rat type VI AC
were purchased (Genosys; TX, USA) and conjugated to bovine serum
albumin (BSA) using m-maleimidobenzoyl-N-hydroxysuccinimide es-
ter [12]. The antiserum was generated by injecting male New Zealand
white rabbits with the BSA-conjugated peptide using standard proce-
dures [12]. This polyclonal anti-peptide antiserum is designated
AC6N. To remove the potential existing anti-BSA IgG, this anti-
type VI AC antiserum was preabsorbed with 0.5% BSA in PBS.
2.2. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blotting
Coding regions of rat type II AC [13], dog type V AC [14], and rat
type VI AC [15] were subcloned into a baculovirus expression vector
(pVL1393). Expressions of types II, V, and VI ACs were carried out
in a recombinant baculovirus-driven Sf21 cell system following the
manufacturer’s protocol (Pharmingen, San Diego, CA, USA). Mem-
brane fractions were prepared as described earlier [7]. SDS-PAGE of
membrane fractions were carried out according to the method of
Laemmli [16]. Western blot analysis was performed as described else-
where [7]. Typically, we used a 1:500 dilution for AC6N antiserum
and 1:1000 for R32, an antiserum broadly reactive with the AC fam-
ily members (Santa Cruz Biotech., Santa Cruz, CA, USA), unless
stated otherwise. The immunoreactive bands were stained using a light
emitting non-radioactive method (ECL, Amersham, UK).
2.3. Immunohistochemistry
Immunostaining of type VI AC using AC6N antiserum (1:500) was
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carried out by the avidin-biotin-peroxidase complex method (ABC) as
previously described [17]. Controls for the speci¢city of AC6N were
performed by incubating sections with AC6N preadsorbed with the
immunizing peptide (designated as the AC6n peptide; 0.5 mg/ml) and
by incubating sections with the preimmune serum. Type VI AC im-
munostaining was abolished almost completely with the preadsorption
treatments. Double immuno£uorescence staining of AC6N antiserum
(1:500) and MAP-2 (1:2000; Boehringer Mannheim Biochemicals,
Indianapolis, IN, USA), or AC6N and tyrosine hydroxylase
(1:5000; Incstar, Stillwater, MN, USA) was carried out as previously
described [18]. For double staining of type VI AC and choline acetyl-
transferase (ChAT), sections were ¢rst immunostained with type VI
AC using DAB as the substrate, then were stained by the immuno-
£uorescent method with a polyclonal goat anti-ChAT antiserum
(1:500; Chemicon, Temecula, CA, USA). The pattern of double im-
munostaining was studied with the aid of a laser confocal microscope
(Bio-Rad, MRC-1000, Hercules, CA, USA). Controls for the speci¢c-
ity of immuno£uorescence were determined by omission of the sec-
ondary antibody in the staining process. Elimination of the secondary
antibody resulted in a loss of immuno£uorescence staining.
2.4. Polymerase chain reaction (PCR) and Southern blot analysis
To amplify the type VI AC fragment, total RNA was puri¢ed from
the indicated rat tissue using silica-gel-based chromatography
(RNeasy Midi, Qiagen, Hilden, Germany). Production of cDNA
was carried out using Superscript* II reverse transcriptase (Gibco-
BRL) following the manufacturer’s protocol from 3.6 Wg of the in-
dicated total RNA. DNA ampli¢cation was performed as described
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Fig. 1. Expression of type VI AC in the central nervous system. A^D: Characterization of an anti-AC VI antibody, AC6N. Immunoblots of
the indicated recombinant proteins (20 Wg per lane) using AC6N (A and D; 1/500 dilution), or AC6N pre-absorbed with AC6n peptide (B; 1/
500 dilution), or a common antibody against adenylyl cyclases, R32 (C, 1/1000). AcNPV: Autographa californica nuclear polyhedrosis virus;
AC2: type II AC; AC5: type V AC; AC6: type VI AC. E: An equal amount (100 Wg) of protein from the hippocampus (HP) or the cerebel-
lum (CE) was loaded to each lane for Western blot analysis using AC6N. The arrow indicates the type VI immunoreactive band. F: The type
VI AC DNA fragments were ampli¢ed from the indicated cDNA prepared in the presence (+) or absence (3) of reverse transcriptase (RT), an-
alyzed by ethidium bromide/agarose (1%) electrophoresis, and transblotted for Southern blot analysis to verify the speci¢city. The predicted
size of the AC VI DNA fragment ampli¢ed was 480 bp. MW: molecular marker; CO: cortex; HP: hippocampus; CE: cerebellum; ST: stria-
tum.
F.-C. Liu et al./FEBS Letters 436 (1998) 92^98 93
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Table 1
Immunostaining patterns of AC6N in the central nervous system of rats
Regions Expression level
Molecular layer +
Granular cell layer +/3
Purkinje cells +
Interpose nu. (Int) ++
Medulla and pons
Spinal trigeminal nu. (SP5O, SP5I, SP5C) +
Spinal trigeminal tract (sp5) +
Nu. lateral lemniscus (DLL, VLL) +
Facial nu. (VII) +
Lateral reticular nu. (LRt) +
Trapezoid body (tz) ++
Inferior olive (IO) ++
Pontine nu. (Pn) ++
Dorsal cochlear nu. (DC) +
Mesencephalon
Superior colliculus (SC) +
Inferior colliculus (IC) +
Red nu. (R) +
Ventral tegmental area (VTA) +
Substantia nigra, compacta (SNc) +
Substantia nigra, reticular (SNr) +
Mesencephalic trigeminal nu. (Me5) +
Diencephalon
Thalamus
Reticular nu. (Rt) ++
Anterodorsal nu. (AD) ++
Anteromedial nu. (AM) ++
Anteroventral nu. (AV) ++
Mediodorsal nu. (MD) +
Laterodorsal nu. (LD) ++
Lateroposterior nu. (LP) ++
Ventrolateral nu. (VL) ++
Ventral posterolateral nu. (VPL) ++
Ventral posteromedial nu. (VPM) ++
Posterior nu. (Po) ++
Subthalamus ++
Hypothalamus
Arcuate nu. (Arc) ++
Lateral hypothalamus (LH) +
Ventromedial nu. (VMH) +
Geniculate
Medial (MGN) ++
Lateral (LGN) ++
Zona incerta ++
Supraoptic nu. (SO) ++
Habenular nu. (Hb) ++
Telencephalon
Basal forebrain
Lateral and medial septal nu. (LS, MS) ++
Horizontal limb of diagonal band (HDB) +
Vertical limb of diagonal band (VDB) ++
Nu. basalis (B) +
Substantia innominata (SI) +
Ventral pallidum (VP) ++
Amygdaloid nuclei
Anterior (AA) ++
Basolateral (BLA) ++
Basomedial (BMA) ++
Bed nu. striata terminalis (BST) ++
Globus pallidus (GP) ++
Caudoputamen (CPu) ++
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earlier [19]. Primers for rat type VI AC gene [15] were as follows: 5P-
ATGCCCCTGCCCGTGGCC-3P and 5P-GTTCATCTGGAAGAA-
GTA-3P. These two primers amplify a DNA fragment of rat VI AC
from bases 14^493 [15]. Expression of type VI AC was veri¢ed by
hybridization with a 32P-labeled, type VI AC-speci¢c primer (5P-
CCGTCCTGCTGGCACCGG-3P, corresponding to rat type VI AC
from bases 395^412).
3. Results and discussion
In order to determine the regional expression of type VI AC
in the central nervous system (CNS), an oligopeptide corre-
sponding to the hypervariable N-terminal region (amino acids
1^19) of rat type VI AC was used to prepare the anti-type VI
AC antiserum, designated as AC6N, in rabbits. There is no
sequence homology between the amino acids 1^19 of type VI
AC and those of other AC isoforms. Recombinant types II, V,
and VI adenylyl cyclase proteins were used as controls to
characterize the speci¢city of AC6N antiserum. Expression
levels of the indicated recombinant AC protein were visual-
ized using a common antibody, R32, which recognizes all ACs
tested (Fig. 1C). As demonstrated in Fig. 1, the AC6N anti-
serum recognized only recombinant type VI AC, but not type
V AC (the closest cousin of type VI AC in the AC family).
Nor did the AC6N antiserum cross-react with type II AC.
Typically, two type VI AC-immunoreactive bands (141 and
150 kDa) were observed. Blocking glycosylation using tunica-
mycin (1 mg/ml) e¡ectively removed the higher type VI AC-
immunoreactive band (data not shown), suggesting that type
VI AC was partially glycosylated in Sf21 cells. Addition of
excess AC6n peptide (amino acids 1V19 of type VI AC)
resulted in the complete disappearance of the two type VI
AC-immunoreactive bands (Fig. 1B). In addition, immuno-
reactivities of type VI AC were detected in the hippocampus
and the cerebellum of rat brain (Fig. 1E). These data demon-
strate that AC6N recognized type VI AC speci¢cally, and was
suitable for the subsequent immunohistochemical analysis of
type VI AC in CNS.
The existence of type VI AC in CNS was also veri¢ed by a
PCR-based detection of the type VI AC transcripts. As shown
in Fig. 1F, a 480-bp DNA fragment of type VI AC was
ampli¢ed from mRNAs of the indicated tissue by a RT-
PCR technique. The speci¢city of the ampli¢ed DNA frag-
ment was con¢rmed by Southern blot analysis using an inter-
nal primer as a radio-labeled probe. No signal was detected
when the reverse transcriptase was omitted in the cDNA syn-
thesis reactions. Our data is consistent with a previous report
by Premont et al. [15] which showed that transcripts of type
VI existed in the rat brain.
We next carried out immunocytochemical analysis of adult
rat brains using the anti-type VI AC antiserum, AC6N. De-
tailed analysis suggest that the type VI AC immunoreactivity
was generally expressed in many brain regions with di¡erent
levels of intensity (Table 1). The speci¢city of type VI AC
immunostaining was demonstrated by preadsorption of
AC6N antiserum with AC6n peptides (the immunizing pep-
tides), which abolished nearly all immunostaining except for
some weak staining still present in Purkinje cells of the cer-
ebellum (data not shown). This residual staining appeared to
be derived from non-speci¢c antibodies present in the antise-
rum, as Purkinje neurons were weakly stained with the pre-
immune serum.
In the hippocampus, a striking pattern of heterogenous ex-
pression of type VI AC immunostaining was observed. Strong
type VI AC immunoreactivity was present in the pyramidal
layers of CA2 and CA3, but not in CA1 (Fig. 2A). The cel-
lular staining indicated that type VI AC was primarily ex-
pressed in the perikarya of pyramidal neurons (Fig. 2B).
High levels of type VI AC immunoreactivity was also present
in the dentate gyrus (Fig. 2C). In contrast to the strong stain-
ing in CA2, CA3 and the dentate gyrus, type VI AC was
expressed at very low levels in the CA1 region (Fig. 2A).
The dramatic shift from the low level of type VI AC expres-
sion in the CA1 region to the high level of expression in the
CA2 region led to a sharp demarcation between these two
regions in the hippocampus (Fig. 2A). There were also type
VI AC-positive cells scattered throughout the hippocampus.
Some of these cells were apparently interneurons in the hippo-
campus (Fig. 2B,C).
ACs have been implicated in several important functions,
including long-term potentiation (LTP) and neurotransmitter
release, of the hippocampus [9,10]. Among all ACs, Ca2-
stimulated ACs have become the focus of study lately since
LTP-inducing tetanic stimulation in the hippocampal area
leads to a Ca2/calmodulin-dependent increase in the cellular
cAMP levels [20]. Such Ca2/calmodulin-mediated stimulation
of postsynaptic AC appears to be generated by activation of
Ca2-stimulated ACs, such as type I AC and type VIII AC
[21,22]. Using a common antibody against all ACs, Mons et
al. [23] previously reported that the densest staining in the
hippocampus was seen in the dentate gyrus with all granular
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Table 1 (continued).
Immunostaining patterns of AC6N in the central nervous system of rats
Regions Expression level
Nu. accumbens (Acb) ++
Hippocampus
Dentate gyrus (DG) ++
CA1 +
CA2 ++
CA3 ++
Subiculum (S) ++
Claustrum (Cl) ++
Cerebral cortex ++
Olfactory tubercle (OTu) +/3
++: intense staining; +: moderate staining; +/3 : weak staining.
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cells strongly labeled. Transcripts of both type I AC and type
VIII AC were found to be expressed at relatively high levels in
the granule cell layers of the dentate gyrus and pyramidal cells
of the CA2 region in the hippocampus [22]. Moreover, high
levels of the type VIII AC transcript were observed in all
pyramidal cells of CA1^CA3 ¢elds [21,24]. Most interestingly,
both LTP in the CA1 region of the hippocampus and spatial
memory were impaired in mice lacking type I AC [10]. Type I
AC was therefore suggested to play an important role in
learning and memory processes. Our data suggest that a
Ca2-inhibitable AC (type VI AC) might be co-expressed
with two Ca2-stimulated ACs (types I and VIII ACs) by
neurons in the hippocampus. Enzymatic analyses showed
that EC50 values of [Ca2]i for stimulation of type I AC
and type VIII AC are 100 and 800 nM, respectively [22], while
type VI AC is signi¢cantly suppressed by submicromolar con-
centrations of [Ca2]i [25]. Impacts of these Ca2-sensitive
ACs on the functions of the hippocampus may be determined
by their di¡erent activation thresholds to [Ca2], by their
other enzymatic properties (see below) and by their subcellu-
lar spatial localizations in synaptic sites.
Type VI AC immunoreactivity was also detected through-
out the cerebral cortex. Strong type VI AC-positive cells were
observed in the deep layers (layers V and VI), whereas lightly
stained cells were found in the upper layers of the cortex (data
not shown). In the basal ganglia, type VI AC immunoreactiv-
ity was detected in the striatum, the nucleus accumbens, the
globus pallidus and the substantia nigra (Table 1). In the
cerebellum, type VI AC immunoreactivity was found in the
interneurons of the molecular layer, Purkinje cells, and gran-
ular cell layer (Table 1). Type VI AC immunoreactivity was
also present in many regions of the hindbrain (Table 1).
To examine whether the type VI AC-immunoreactive cells
were neurons, we carried out double immunostaining for type
VI AC and microtubule-associated protein 2 (MAP-2), which
is a marker for neurons [26]. The results show that type VI
AC-positive cells in most areas examined co-express MAP-2
(Fig. 3A,B). Thus, the detected type VI AC immunoreactivity
was present in cells with neuronal phenotype. We and other
laboratories have previously reported that this type VI AC
can be suppressed by physiologically relevant concentrations
of [Ca2]i [25], by PKC [7] and by PKA [11]. Since cAMP/
PKA, calcium, and PKC are three very important signal mes-
sengers generally used in the nervous system, type VI AC
appears to integrate multiple signals and might provide an
exquisite mechanism for the ¢ne-tuning of cAMP synthesis
by Ca2, PKA, and PKC in neurons. In contrast, most of
the astrocytes identi¢ed by positive immunoreactivity of glial
¢brillary acidic protein (a marker of astrocytes) were negative
for type VI AC immunoreactivity, except some astrocytes in
speci¢c areas including the hippocampus and the cerebellum
(data not shown). These data suggest that type VI AC protein
might be more important in regulating the physiological func-
tions in neurons than those in astrocytes.
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Fig. 2. Photomicrographs illustrating type VI AC immunoreactivity in the hippocampus. A: Strong type VI AC-immunoreactive cells appear in
CA2, CA3, the dentate gyrus (DG), and subiculum (SB). By contrast, very low levels of type VI AC immunoreactivity are present in CA1. The
arrows point to the transition zone from type VI AC-poor CA1 to type VI AC-rich CA2. B: High magni¢cation of CA2 region. The pyramidal
neurons of CA2 region are highly immunoreactive for type VI AC (arrow). A few scattered interneurons are also type VI AC-positive (arrow-
head). C: High magni¢cation of the dentate gyrus. Many type VI AC-positive granular cells (large arrow) are present in the dentate gyrus. A
few interneurons (small arrow) and small glia-like cells (arrowheads) also appear in this area. Scale bars in A indicate 200 Wm, in B (for B and
C) indicate 50 Wm.
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The di¡erential expression of type VI AC protein within a
brain region suggests that type VI AC molecules may be
coupled to speci¢c signal transduction pathways in di¡erent
neuronal populations. We tested this possibility by performing
double immunostaining of type VI AC and markers of di¡er-
ent neurotransmitter systems, including dopaminergic and
cholinergic systems. For the dopaminergic system, double im-
muno£uorescence of type VI AC and tyrosine hydroxylase
(TH, a synthetic enzyme for catecholamine) showed that
TH-positive dopaminergic neurons in the pars compacta of
substantia nigra co-expressed type VI AC (Fig. 3C,D). We
also carried out double immunostaining analysis of type VI
AC and DARPP-32 (dopamine- and adenosine 3P :5P-mono-
phosphate-regulated phosphoprotein). DARPP-32 is a mole-
cule known to be associated with D1 dopamine receptors [27].
Our results showed that type VI AC and DARPP-32 were co-
localized in neurons of the caudoputamen (data not shown).
Thus, type VI AC protein was expressed in the mesostriatal
dopaminergic system. For the cholinergic system, double im-
munostaining of type VI AC and choline acetyltransferase
(ChAT) demonstrated the co-expression of ChAT and type
VI AC in the neurons of basal forebrain including the nucleus
basalis of Meynert and substantia innominata (Fig. 3E,F).
These results showed that type VI AC protein is expressed
in dopaminergic and cholinergic neurons. In addition, type
VI AC immunoreactivity was detected in neurons of several
brain regions that are known to use glutamate and GABA as
neurotransmitters, such as the hippocampus and the striatum
(Table 1). Expression of type VI AC protein therefore is ap-
parently associated with the glutamatergic and GABAergic
systems. Collectively, type VI AC may participate in regula-
tion of the classical neurotransmitter systems, including dop-
amine, acetylcholine, glutamate, and GABA.
In addition to their di¡erent sensitivities toward calcium,
the enzymatic properties of type VI AC compared to other
ACs expressing in CNS are also di¡erent. Harry et al. [2] have
recently reported that stimulation of type VI AC by GsK can
be analyzed using a two-site model which is mechanistically
very di¡erent from those of types I and II ACs. The suscept-
ibility of each individual AC to inhibition by GiK is also
di¡erent [3]. Such fundamentally di¡erent regulation of indi-
vidual AC by GK proteins might contribute to variable re-
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Fig. 3. Existence of type VI AC immunoreactivities in di¡erent neurotransmitter systems. A, B: Confocal images illustrating coexpression of
type VI AC (A) and MAP-2 (B) in the cerebral cortex (arrows). C, D: Confocal images of double immuno£uorescent staining of type VI AC
(C) and TH (D) in the same ¢eld of the substantia nigra pars compacta. All TH-positive dopaminergic neurons co-express type VI AC (ar-
rows). A few type VI AC-positive cells, however, do not express TH (arrowhead). E, F: Photomicrographs of double immunostaining of type
VI AC (E) and ChAT (F) in the same ¢eld of the basal forebrain. Type VI AC-positive cells appear black in the lighter background in E,
whereas ChAT-positive cells appear as white cells in F. ChAT is expressed in some but not all type VI AC-positive cells (arrows). ACVI: type
VI AC. Scale bars in A, C, and E indicate 20 Wm.
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sponses to cAMP-regulating hormones in di¡erent tissues. In
addition, the basal activity of type VI AC is signi¢cantly low-
er than that of type II AC [28], suggesting that neurons dom-
inantly expressing type VI AC might have a lower basal
cAMP level than do those overbearingly expressing type II
AC. The signi¢cance of the above ¢nding is tremendous since
the basal cAMP levels, which determine the basal protein
kinase A activity, play a critical role in various important
physiological processes [29,30].
In summary, we have demonstrated that type VI AC is
widely expressed in CNS, mainly in neurons. This calcium-
inhibitable AC is likely to integrate diverse signals (cAMP/
PKA, calcium, and PKC) in neurons, and plays an important
role in CNS.
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